Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Regulatory science for AI-based software as a medical device in computational pathology and biomarker-driven drug development.

PMID: 42436740 ·

Y, a, e, l, , L, i, e, b, e, s, -, P, e, e, r, ;, , S, h, l, o, m, o, , C, z, e, i, s, l, e, r, ;, , R, a, c, h, e, l, , B, r, o, d, e, r, i, c, k, ;, , M, a, n, u, e, l, a, , V, e, c, s, l, e, r, ;, , Y, a, i, r, , H, e, l, l, e, r, ;, , C, h, a, i, m, , L, i, n, h, a, r, t, ;, , J, o, s, e, p, h, , M, o, s, s, e, l, ;, , J, o, c, h, e, n, , K, , L, e, n, n, e, r, z

JournalJournal of pathology informatics
Year
PMID42436740

Abstract

Artificial intelligence (AI)-enabled software is increasingly integrated into digital and computational pathology, driving new regulatory and quality management requirements that extend beyond traditional laboratory practice and classical medical-device oversight. Practical, experience-based guidance on balancing development agility with global regulatory readiness remains limited for biomarker developers and translational pathologists navigating the convergence of AI governance, cybersecurity,

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.

↑